A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few years now.

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

YORK, Pa. — Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance to help some people treat depression. The Federal Drug ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...